<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39384334</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1447-0756</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Oct</Month><Day>09</Day></PubDate></JournalIssue><Title>The journal of obstetrics and gynaecology research</Title><ISOAbbreviation>J Obstet Gynaecol Res</ISOAbbreviation></Journal><ArticleTitle>Influence of COVID-19 on the clinical characteristics of patients with uterine cervical cancer in Japan: A single-center retrospective study.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1111/jog.16119</ELocationID><Abstract><AbstractText Label="AIM" NlmCategory="OBJECTIVE">This study investigated the impact of coronavirus disease 2019 (COVID-19) on the clinical characteristics and interregional movement of patients with uterine cervical cancer.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This study included 1189 patients who underwent treatment for cervical cancer, including cervical intraepithelial neoplasm and adenocarcinoma in situ, at our hospital in Tokyo, Japan, in 2017-2018 and in 2021, before and after the pandemic, respectively. The patients' clinical information was compared during both periods. The clinical stage was unified using the International Federation of Gynecology and Obstetrics (FIGO) 2008 staging.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The number of patients treated for cervical cancer was 355, 420, and 414 in 2017, 2018, and 2021, respectively. The percentage of invasive carcinomas significantly increased from 158 (44.5%) and 196 (46.7%) to 219 (52.9%) (p = 0.049). In all periods, no significant differences were observed in median age, histological type, and treatment. The proportions of FIGO Stage IA1 were significantly elevated from 3.9% and 3.8% to 11.4% (p &lt; 0.001). The percentage of patients from prefectures other than Tokyo significantly increased from 34.9% to 40.8% (p = 0.049). Furthermore, the proportion of patients with invasive carcinoma in private clinics increased from 28.0% to 37.9% (p = 0.014).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The number of patients with invasive carcinoma and the percentage of patients with invasive carcinoma referred from private clinics increased, indicating that the COVID-19 pandemic influenced patients to delay consultations. Furthermore, the surge in patients from other prefectures indicates that medical resources were more limited in rural areas, another impact of COVID-19.</AbstractText><CopyrightInformation>© 2024 Japan Society of Obstetrics and Gynecology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Murakami</LastName><ForeName>Atsushi</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-1972-0134</Identifier><AffiliationInfo><Affiliation>Department of Gynecology, The Cancer Institute Hospital of JFCR, Koto-ku, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nomura</LastName><ForeName>Hidetaka</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-2742-5282</Identifier><AffiliationInfo><Affiliation>Department of Gynecology, The Cancer Institute Hospital of JFCR, Koto-ku, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abe</LastName><ForeName>Akiko</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Gynecology, The Cancer Institute Hospital of JFCR, Koto-ku, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fusegi</LastName><ForeName>Atsushi</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-6044-2781</Identifier><AffiliationInfo><Affiliation>Department of Gynecology, The Cancer Institute Hospital of JFCR, Koto-ku, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aoki</LastName><ForeName>Yoichi</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0003-0481-9892</Identifier><AffiliationInfo><Affiliation>Department of Gynecology, The Cancer Institute Hospital of JFCR, Koto-ku, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Omi</LastName><ForeName>Makiko</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Gynecology, The Cancer Institute Hospital of JFCR, Koto-ku, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tanigawa</LastName><ForeName>Terumi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Gynecology, The Cancer Institute Hospital of JFCR, Koto-ku, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Okamoto</LastName><ForeName>Sanshiro</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Gynecology, The Cancer Institute Hospital of JFCR, Koto-ku, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yunokawa</LastName><ForeName>Mayu</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Gynecology, The Cancer Institute Hospital of JFCR, Koto-ku, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kanao</LastName><ForeName>Hiroyuki</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Gynecology, The Cancer Institute Hospital of JFCR, Koto-ku, Tokyo, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>Australia</Country><MedlineTA>J Obstet Gynaecol Res</MedlineTA><NlmUniqueID>9612761</NlmUniqueID><ISSNLinking>1341-8076</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">cancer of the cervix</Keyword><Keyword MajorTopicYN="N">gynecologic oncology</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>10</Day><Hour>4</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>10</Day><Hour>4</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>9</Day><Hour>21</Hour><Minute>23</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39384334</ArticleId><ArticleId IdType="doi">10.1111/jog.16119</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>WHO Director‐General's opening remarks at the media briefing on COVID‐19. [cited 11 March 2020]. Available from: https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020</Citation></Reference><Reference><Citation>Spicer J, Chamberlain C, Papa S. Provision of cancer care during the COVID‐19 pandemic. Nat Rev Clin Oncol. 2020;17:329–331. https://doi.org/10.1038/s41571-020-0370-6</Citation></Reference><Reference><Citation>Hanna TP, Evans GA, Booth CM. Cancer, COVID‐19 and the precautionary principle: prioritizing treatment during a global pandemic. Nat Rev Clin Oncol. 2020;17:268–270. https://doi.org/10.1038/s41571-020-0362-6</Citation></Reference><Reference><Citation>Mayor S. COVID‐19: impact on cancer workforce and delivery of care. Lancet Oncol. 2020;21:633. https://doi.org/10.1016/s1470-2045(20)30240-0</Citation></Reference><Reference><Citation>Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424. https://doi.org/10.3322/caac.21492</Citation></Reference><Reference><Citation>Small W Jr, Bacon MA, Bajaj A, Chuang LT, Fisher BJ, Harkenrider MM, et al. Cervical cancer: a global health crisis. Cancer. 2017;123:2404–2412. https://doi.org/10.1002/cncr.30667</Citation></Reference><Reference><Citation>Davies JM, Spencer A, Macdonald S, Dobson L, Haydock E, Burton H, et al. Cervical cancer and COVID‐an assessment of the initial effect of the pandemic and subsequent projection of impact for women in England: a cohort study. BJOG. 2022;129:1133–1139. https://doi.org/10.1111/1471-0528.17098</Citation></Reference><Reference><Citation>Antunes D, Mendonça L, Melo Â, Gonçalves S, Nogueira Martins F, Nogueira MN. Impact of the COVID‐19 pandemic on diagnosis and management of gynecological cancer: a single‐center analysis. Medicina (Kaunas). 2022;58:1862. https://doi.org/10.3390/medicina58121862</Citation></Reference><Reference><Citation>Elemes S, Stachteas P, Haidich AB, Mamopoulos A, Smyrnakis E. The impact of the COVID‐19 pandemic on breast and cervical cancer screening: a systematic review. In Vivo. 2023;37:1455–1476. https://doi.org/10.21873/invivo.13230</Citation></Reference><Reference><Citation>Nogami Y, Makabe T, Komatsu H, Kawana K, Okamoto A, Mikami M, et al. Impact of COVID‐19 on cervical cancer screening in Japan: a survey of population‐based screening in urban Japan by the Japan Society of Gynecologic Oncology. J Obstet Gynaecol Res. 2022;48:757–765. https://doi.org/10.1111/jog.15130</Citation></Reference><Reference><Citation>Nogami Y, Komatsu H, Makabe T, Hasegawa Y, Yokoyama Y, Kawana K, et al. Impact of COVID‐19 on gynecologic cancer treatment in Japan: a nationwide survey by the Japan Society of Gynecologic Oncology (JSGO). J Gynecol Oncol. 2022;33:e8. https://doi.org/10.3802/jgo.2022.33.e8</Citation></Reference><Reference><Citation>Komatsu H, Ikeda Y, Kawana K, Nagase S, Yoshino K, Yamagami W, et al. Impact of COVID‐19 on gynecological cancer incidence: a large cohort study in Japan. Int J Clin Oncol. 2024;29:72–77. https://doi.org/10.1007/s10147-023-02431-w</Citation></Reference><Reference><Citation>Kanda Y. Investigation of the freely available easy‐to‐use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013;48:452–458. https://doi.org/10.1038/bmt.2012.244</Citation></Reference><Reference><Citation>Ferrara P, Dallagiacoma G, Alberti F, Gentile L, Bertuccio P, Odone A. Prevention, diagnosis and treatment of cervical cancer: a systematic review of the impact of COVID‐19 on patient care. Prev Med. 2022;164:107264. https://doi.org/10.1016/j.ypmed.2022.107264</Citation></Reference><Reference><Citation>Martins TR, Witkin SS, Mendes‐Correa MC, de Godoy AS, Cury L, Balancin ML, et al. Impact of the COVID‐19 pandemic on cervical cancer screening in Sao Paulo state, Brazi. Acta Cytol. 2023;67:388–394. https://doi.org/10.1159/000529249</Citation></Reference><Reference><Citation>Ramirez PT, Chiva L, Eriksson AGZ, Frumovitz M, Fagotti A, Gonzalez Martin A, et al. COVID‐19 global pandemic: options for management of gynecologic cancers. Int J Gynecol Cancer. 2020;30:561–563. https://doi.org/10.1136/ijgc-2020-001419</Citation></Reference><Reference><Citation>Dewan A, Mitra S, Aggarwal S, Barik S, Kaur I, Umesh P, et al. Management of cervical cancer during the corona virus disease‐19 (COVID‐19) era. Br J Radiol. 2021;94:20200686. https://doi.org/10.1259/bjr.20200686</Citation></Reference><Reference><Citation>Wickenheisser NE, Dillon M, Broadwater G, Zacherl K, Bixel K, Levine M, et al. Radical hysterectomy case volume and cervical cancer treatment in the era of COVID‐19: a multi‐site analysis of National Cancer Institute‐designated Comprehensive cancer centers. Gynecol Oncol. 2023;179:70–78. https://doi.org/10.1016/j.ygyno.2023.10.010</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>